Co-Diagnostics raises $3.0M in private placement of stock and warrants at $1.821/unit

Co-Diagnostics, Inc.

Gross proceeds of $3.0M from sale of 1.65M shares/pre-funded warrants and 3.29M common warrants.
Common warrants exercisable immediately at $1.571/share, expire in five years; pre-funded warrants at $0.0001.
Offering priced at-the-market under Nasdaq rules; expected to close May 21, 2026.
Maxim Group LLC acted as sole placement agent; net proceeds for general corporate purposes and working capital.
Company agreed to file a resale registration statement within 15 days to register the securities.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Co-Diagnostics, Inc. entered into Securities Purchase Agreement with certain institutional and accredited investors valued at aggregate gross proceeds of $3.0 million (effective 2026-05-19).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional and accredited investors
Value: aggregate gross proceeds of $3.0 million
Effective: 2026-05-19

Exact text from the filing

On May 19, 2026, Co-Diagnostics, Inc. (the “Company”), entered into a private placement transaction (the “Private Placement”), pursuant to a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional and accredited investors (the “Purchasers”) for aggregate gross proceeds of $3.0 million

View on SEC.gov

Browse all material agreements →

Co-Diagnostics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-024738

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.